Amgen Looks to Expand Apremilast Plaque Psoriasis Indication
Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo.
Psoriasis
Bimekizumab May be Superior to Ustekinumab for Plaque Psoriasis
More patients met targets for improvement in Psoriasis Area and Severity Index, Investigator’s Global Assessment response at week 16
Deucravacitinib Superior to Apremilast in Second Psoriasis Trial
The double-blind, placebo and active-controlled POETYK PSO-2 trial included 1022 patients 18 years of age and older with moderate to severe plaque psoriasis.
Clinical Challenge: Rash on Soles of Feet
A woman presents for evaluation of a rash affecting both feet that prevents her from walking properly because of pain.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
RediTrex Now Available for RA, pJIA, Psoriasis Treatment
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Deucravacitinib Shows Superiority to Apremilast in Psoriasis Trial
A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.
Enstilar Labeling Updated With Data on Long-Term Use in Plaque Psoriasis
The update was based on data from the phase 3 PSO-LONG trial, a randomized, double-blind, vehicle-controlled study that evaluated the long-term use of Enstilar Foam in 545 adults.
Bimekizumab Under Review for Plaque Psoriasis
The BLA is supported by data from the phase 3 BE VIVID, BE READY, and BE SURE studies.
Shift Seen to Newer Agents to Treat Psoriasis
Biologics and small molecule inhibitors increasingly used for treatment of newly diagnosed psoriasis.
